OBJECTIVES: Mitral regurgitation (MR) is common in patients with end-stage heart failure. We assessed the effect of performing concomitant mitral valve repair during continuous-flow left ventricular assist device (CF-LVAD) implantation in patients with severe preoperative MR.
Mitral regurgitation (MR) is a common finding in patients with end-stage heart failure. One consequence of left ventricular remodelling and dilatation is reduced coaptation of the mitral leaflets, which often leads to severe regurgitation that may worsen heart failure symptoms [1] . Performing concomitant procedures at the time of left ventricular assist device (LVAD) implantation prolongs surgical and cardiopulmonary bypass (CPB) times. Initial reports have shown increased mortality in patients who undergo any concomitant procedures at the time of LVAD insertion [2] . However, recent publications report that not all concomitant procedures affect survival [3] [4] [5] . In the particular case of mitral valve repair, there is evidence that this procedure may cause an additional reduction in pulmonary vascular resistance (PVR), improving morbidity, mortality and cardiac function and allowing some patients to become eligible to undergo transplantation [6] .
The current study aimed to evaluate the effect of concomitant mitral valve repair at the time of contemporary, continuous-flow LVAD (CF-LVAD) implantation in patients with severe preoperative MR.
METHODS

Study cohort
Institutional Research Board approval was obtained before we undertook a retrospective review of our database. In this single-centre review, we first identified all patients who received a CF-LVAD between December 1999 and December 2013 (n = 469). Then, from these patients, we identified those who had severe preoperative MR (n = 78) and further stratified them according to whether they underwent concomitant mitral valve repair.
Primary end-points
Date related to demographics, surgical indications, echocardiographic and haemodynamic parameters, perioperative characteristics and late clinical outcomes were reviewed and summarized for all patients. Our primary aim was to determine overall survival.
Statistical analysis
Patient-related data were obtained from the Texas Heart Institute medical records. Follow-up data were collected from hospital and clinic medical records. Categorical variables are presented as percentages and continuous variables as mean ± standard deviation. A univariate analysis was performed. The 2-sample t-test was used for continuous variables and either the v 2 test or the Fisher's exact test was used for categorical variables. Cox proportional hazard regression analysis was used to identify independent predictors of survival, and log-rank methods were used to compare the survival rates of the 2 groups. For all analyses, P-values are 2-sided, and P-value <0.05 was considered significant. Analyses were conducted with STATA software version 13 (Stata Corp LP, Collage Station, TX, USA).
Surgical repair
Depending on surgeon's preference, patients underwent mitral valve repair at the time of the implant. All mitral valve repairs were performed through the ventriculotomy used for the inflow implant [7] . In all cases, the repair was performed with an edgeto-edge stitch, as described by Maisano et al. [8] .
We considered that the edge-to-edge stitch would be sufficient to prevent severe degrees of MR, in addition to the LVAD unloading effect. The ventriculotomy promotes a direct access to the mitral valve, avoiding the need to do additional incisions.
RESULTS
Complete follow-up data were available for all 469 patients who underwent CF-LVAD implantation (mean follow-up, 2.5 ± 2.4 years; maximum, 13.3 years). Of the 78 patients identified as having severe MR, 21 underwent concomitant valve repair at the time of CF-LVAD implantation (repair group) and 57 did not (non-repair group). The demographic, preoperative haemodynamic and perioperative characteristics of these patients are summarized in Table 1 . The 2 groups showed no statistically significant differences with regard to demographics, except that the non-repair group had a higher percentage of INTERMACS Class 1 patients (16.98 vs 9.52%, P = 0.039). The only other demographic variable that approached statistical significance was the percentage of bridge-to-transplant patients, which was found to be higher in the non-repair group (61.4 vs 38.1%, P = 0.078).
No significant differences were found in the preoperative haemodynamics of the repair and non-repair groups; however, patients in the repair group tended to have a higher central venous pressure (14.76 vs 12.07 mmHg, P = 0.24), pulmonary capillary wedge pressure (31.86 vs 27.79 mmHg, P = 0.18), mean pulmonary artery pressure (42.47 vs 39.0 mmHg, P = 0.23) and PVR (3.92 vs 3.6 Wood units, P = 0.66).
In the repair group, 100% of patients received a HeartMate II (Thoratec, Pleasanton, CA, USA) implant, whereas only 63.16% of the patients in the non-repair group received a HeartMate II. A HeartWare HVAD (HeartWare, Danvers, MA, USA) was implanted in 21.05% of the non-repair patients, and the remaining 15.19% received a Jarvik 2000 (Jarvik Heart, Inc., New York, NY, USA). In all cases, device selection was based on transplant candidacy and surgical team preference. As previously stated, all mitral valve repairs were performed through the ventriculotomy used to insert the LVAD inlet cannula. The CPB time was significantly longer in the repair group than in the non-repair group (109.4 vs 82.09 min, P = 0.0042). The need for perioperative right ventricular mechanical support was slightly higher in the non-repair group than in the repair group, but the difference was not significant (14.04 vs 9.52%, P = 0.721).
At discharge, the mean speed for the HeartMate II devices was 8300 ± 881.38 rpm in the repair group, whereas it was 8866 ± 877.82 rpm in the non-repair group (P = 0.03). The mean speed for the HeartWare HVADs was 2453 ± 180 rpm and that for the Jarvik 2000 devices was 10 000 ± 0 rpm.
In the last echocardiographic study before discharge, 56.14% of the patients in the non-repair group showed improvement in MR severity, whereas 76.19% of patients in the repair group showed improvement (P = 0.124). In this same echocardiographic study, more than 75% of patients in the repair group showed mild or trace MR. In contrast, 41.8% of patients in the non-repair group had moderate MR. At follow-up, both groups showed a reduction in PVR. Although the difference was not statistically significant, the repair group showed a trend towards a greater reduction in PVR, when compared with the non-repair group (1.1 vs 0.8, P = 1.0)
Results from the survival analysis suggested a trend towards improved survival in the repair group (Fig. 1) . Multivariable regression analysis showed no significant independent predictors of survival (mitral valve repair: odds ratio 0.4, 95% confidence interval 0.8-1.5; P = 0.2).
The incidence of other postoperative adverse events, such as cerebrovascular accident, gastrointestinal bleeding, heart failure (new onset or worsening shortness of breath, orthopnoea, abdominal swelling or oedema), driveline infection or thrombosis, were similar for both groups (Table 2) . Although the results were not significant, the Kaplan-Meier curve illustrating freedom from heart failure readmission suggested a possible protective effect of concomitant mitral valve repair (hazard ratio 0.64, P = 0.455) (Fig. 2) .
DISCUSSION
Severe MR is a well-described factor in heart failure. Addressing it at the time of LVAD placement carries the inherent risk of prolonged operative time. For our study, we reviewed the largest contemporary experience of CF-LVAD implantations and identified 78 patients with severe preoperative MR, 21 of whom underwent mitral valve repair at the time of CF-LVAD implantation. We conclude that despite the lack of statistical significance, trends towards improved survival and a lower incidence of postoperative heart failure events in these patients suggest that concomitant mitral valve repair may be beneficial.
MR is common in patients with heart failure and is a prognostic factor for these patients. MR causes a continuous increase in left-side filling pressures, which in turn causes increases in pulmonary capillary wedge pressure and PVR. In patients with endstage heart failure, PVR is one of the determinants of transplant candidacy. Unloading the left ventricle with a CF-LVAD has been shown to have a positive effect on PVR reduction [9] [10] [11] . Taghavi et al. [6] have shown that PVR reduction is greater in patients who undergo mitral valve repair concomitant with LVAD implantation than in those who undergo LVAD implantation alone. Similar results were found in our study population; both groups showed a reduction in PVR, but the repair group showed a trend towards a greater reduction, although the difference between the 2 groups was not statistically significant. Except for the effect on PVR reduction, few studies have assessed the effects of mitral valve repair on postoperative survival and morbidity in patients with severe MR at the time of LVAD implantation. Recently, Stulak et al. [12] published a multicentre report that showed improved survival in patients who had significant uncorrected MR preoperatively, when compared with patients who had lower degrees of MR preoperatively. The authors proposed that patients with more severe MR are the ones who also have larger left ventricular end-diastolic dimension (LVEDD). They suggested that patients with more dilated ventricles (i.e. with a larger LVEDD) are mainly affected by left ventricular dysfunction and would benefit most from LVAD support. However, in our population, LVAD support alone did not seem to be sufficient to unload the left-side chambers. Despite the significantly higher LVAD speeds in the non-repair group, the repair group had a higher percentage of patients with trace/mild regurgitation and a higher percentage who showed improvement in MR severity. We believe that the additional unloading effect and the consequent reduction in left-side filling pressures brought about by the mitral valve repair may have contributed to the additional reduction in PVR and the lower incidence of heart failure-related readmissions seen in the repair group.
When performing concomitant procedures during LVAD implantation, some of the main concerns are the extended CPB time and the need for additional heart incisions. Transapical mitral valve repair via ventriculotomy has been shown to be feasible and reproducible for different surgical teams [7] and has the main advantage of avoiding an extra cardiac incision.
Limitations
This study had the common limitations inherent to retrospective cohorts, such as selection bias and the need for a larger population to achieve statistical significance. Furthermore, although this study reviewed data from one of the largest single-centre experiences with mitral valve repair at the time of LVAD implantation, the sample size was still small, which limited the statistical power. Thus, further collaborative studies or registry reviews are warranted. However, the single-centre format was beneficial in that the surgical and postoperative management procedures were uniform throughout the study period.
CONCLUSIONS
Despite the increased CPB time, a trend towards improved survival was seen in patients with severe MR who underwent concomitant mitral valve repair at the time of LVAD implantation.
In addition, mitral valve repair was associated with greater reductions in PVR and readmission rates due to heart failure events. Given the known relationship between severe MR and mortality, further study is encouraged to confirm the value of mitral valve repair in patients undergoing LVAD implantation.
We assessed the results of concomitant mitral repair at the time of LVAD insertion. However, mitral repair could be considered during patients' follow-up. Minimally invasive or percutaneous repair may be an option. However, their feasibility would need to be assessed in further studies.
